Literature DB >> 3879182

Pharmacokinetics of the trimethoprim-sulphamethoxazole combination in the elderly.

O Varoquaux, D Lajoie, C Gobert, P Cordonnier, C Ducreuzet, M Pays, C Advenier.   

Abstract

The pharmacokinetics of a co-trimoxazole preparation (Bactrim Forte) containing trimethoprim (TMP) 160 mg and sulphamethoxazole (SMZ) 800 mg were determined in six young adults (29.3 +/- 4.4 s.d. years) and six elderly people (78.6 +/- 6.6 s.d. years). Following oral administration of a single dose, the pharmacokinetic parameters of SMZ and its N4-acetylated metabolite (N4SMZ) were similar in both groups. However Cmax of TMP was greater (2.06 +/- 0.29 s.d. vs 1.57 +/- 0.32 s.d. mg l-1; P less than 0.01) and its area under the curve was larger (34.30 +/- 6.98 s.d. vs 23.87 +/- 3.82 s.d. mg l-1 h; P less than 0.001) in elderly people than in younger subjects. Total clearance (CL/F) of TMP normalized to body weight was not significantly different in the two groups. There was no significant difference in serum protein binding of TMP and SMZ between the two groups. Urinary excretion of TMP, SMZ and N4SMZ was reduced by about 50% in the elderly compared to the young subjects. Renal clearance of TMP was significantly lower in the elderly group (19 +/- 10 s.d. vs 55 +/- 14 s.d. ml h-1 kg-1; P less than 0.001). Renal clearance of SMZ was not significantly different in the two groups. A study of plasma concentrations of TMP, SMZ and N4SMZ during continuous dosing in seven elderly patients treated for urinary or respiratory infections showed that steady state was reached after 3 days of treatment and that plasma drug concentrations were about two to three times higher than those observed after a single dose.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3879182      PMCID: PMC1400827          DOI: 10.1111/j.1365-2125.1985.tb05114.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Pharmacokinetic and clinical implications of quinidine protein binding.

Authors:  E Woo; D J Greenblatt
Journal:  J Pharm Sci       Date:  1979-04       Impact factor: 3.534

2.  Pharmacokinetics of trimethoprim and its combination with sulfamethoxazole in man after single and chronic oral administration.

Authors:  H Nolte; H Büttner
Journal:  Chemotherapy       Date:  1973       Impact factor: 2.544

3.  Pharmacokinetics of trimethoprim and sulfamethoxazole in normal subjects and in patients with renal failure.

Authors:  P G Welling; W A Craig; G L Amidon; C M Kunin
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

4.  Pharmacokinetics of sulfamethoxazole plus trimethoprim in man and their distribution in the rat.

Authors:  D E Schwartz; J Rieder
Journal:  Chemotherapy       Date:  1970       Impact factor: 2.544

5.  Determination of trimethoprim, sulphamethoxazole and its N4-acetyl metabolite in biological fluids by high-performance liquid chromatography.

Authors:  O Spreux-Varoquaux; J P Chapalain; P Cordonnier; C Advenier; M Pays; L Lamine
Journal:  J Chromatogr       Date:  1983-05-13

Review 6.  Drug therapy: drug disposition in old age.

Authors:  D J Greenblatt; E M Sellers; R I Shader
Journal:  N Engl J Med       Date:  1982-05-06       Impact factor: 91.245

Review 7.  Pharmacokinetics in the elderly.

Authors:  J Crooks; K O'Malley; I H Stevenson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

8.  Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole).

Authors:  R B Patel; P G Welling
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

9.  Effect of age and sex on human drug metabolism.

Authors:  K O'Malley; J Crooks; E Duke; I H Stevenson
Journal:  Br Med J       Date:  1971-09-11
  9 in total
  14 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

2.  Simulated antibiotic exposures in an in vitro hollow-fiber infection model influence toxin gene expression and production in community-associated methicillin-resistant Staphylococcus aureus strain MW2.

Authors:  Solen Pichereau; Madhulatha Pantrangi; William Couet; Cedric Badiou; Gerard Lina; Sanjay K Shukla; Warren E Rose
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

3.  Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model.

Authors:  José M Entenza; Andreas Haldimann; Marlyse Giddey; Sergio Lociuro; Stephen Hawser; Philippe Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

Review 4.  Compositional dynamics of the human intestinal microbiota with aging: implications for health.

Authors:  B Lakshminarayanan; C Stanton; P W O'Toole; R P Ross
Journal:  J Nutr Health Aging       Date:  2014-11       Impact factor: 4.075

5.  Consideration of the uses and risks of co-trimoxazole from the therapeutic point of view.

Authors:  H Lode
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 6.  Plasma protein binding of drugs in the elderly.

Authors:  S M Wallace; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

8.  Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis.

Authors:  Allen C Cheng; Emma S McBryde; Vanaporn Wuthiekanun; Wirongrong Chierakul; Premjit Amornchai; Nicholas P J Day; Nicholas J White; Sharon J Peacock
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

9.  Effects of salbutamol on the absorption and disposition of sulphamethoxazole in adult volunteers.

Authors:  G I Adebayo; T O Ogundipe
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jan-Mar       Impact factor: 2.441

10.  Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.

Authors:  N Alsaad; J A Dijkstra; O W Akkerman; W C M de Lange; D van Soolingen; J G W Kosterink; T S van der Werf; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.